Table 4.

Symptoms and adverse effects reported by extensive (EMs) and poor (PMs) metabolizers during 12 weeks' treatment with racemic nebivolol 5 mg

	EMs (n = 23) n (%)	PMs (n = 14) n (%)
Heart rate and rhythm disorders
Bradycardia	2 (8%)	0
Circulation
Peripheral oedema	1 (4%)	1 (7%)
Respiratory system
Cough	2 (8%)	1 (7%)
Dyspnea	1 (4%)	1 (7%)
Sinusitis	0	2 (15%)
Upper tract infection	4 (16%)	0
Gastrointestinal system
Dyspepsia	0	1 (7%)
Nausea	1 (4%)	1 (7%)
Urinary system
Cystitis	0	1 (7%)
Musculoskeletal system
Back pain	3 (13%)	1 (7%)
Leg pain	1 (4%)	1 (7%)
Nervous system
Dizziness	1 (4%)	1 (7%)
Headache	2 (8%)	3 (21%)
Hyperkinesia	0	1 (7%)
Hypoaesthesia	1 (4%)	1 (7%)
General weakness	2 (8%)	0
Head/eyes
External otitis	0	1 (7%)